ASCO 2023 Meeting Report — Hematologic Malignancies

The 2023 American Society of Clinical Oncology (ASCO) annual meeting, held June 2 to 6 in Chicago, highlighted important advances in treatment across a broad spectrum of hematologic malignancies. Here, Associate Editor Dr. Michael Williams reviews several key trials in myelodysplastic syndromes, Hodgkin lymphoma, and lymphocytic leukemia.

Luspatercept Reduces RBC Transfusion Dependence in Patients with Lower-Risk Myelodysplastic Syndromes and Anemia

First-line treatment with luspatercept, compared with epoetin alfa, improves anemia and reduces need for red blood cell (RBC) transfusions in transfusion-dependent adults with lower-risk myelodysplastic syndromes (MDS), according to a planned interim analysis from the industry-sponsored, phase 3 C…